INCB186748

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

INCB186748 is under investigation for the treatment of colorectal cancer and other solid tumors; it may be particularly useful in patients with mutations or alterations affecting the Wnt/ -catenin pathway; clinical trials are ongoing to evaluate its efficacy and safety in combination with other agents.

Mechanism of Action

INCB186748 is an investigational small molecule inhibitor of the Wnt/ -catenin signaling pathway, which is often dysregulated in colorectal cancer; it works by inhibiting porcupine-mediated secretion of Wnt ligands.

Side Effects

Fatigue; nausea; diarrhea; vomiting; decreased appetite; weight loss

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06818812 Phase 1
Active, not recruiting
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
United States

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
785 trials
Leucovorin
Other Medications
646 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.